| Literature DB >> 26696086 |
Iris M Noebauer-Huhmann1, Marc-André Weber2, Radhesh K Lalam3, Siegfried Trattnig1, Klaus Bohndorf1, Filip Vanhoenacker4, Alberto Tagliafico5, Carla van Rijswijk6, Joan C Vilanova7, P Diana Afonso8, Martin Breitenseher9, Ian Beggs10, Philip Robinson11, Milko C de Jonge12, Christian Krestan1, Johan L Bloem6.
Abstract
Soft tissue sarcomas are rare, but early, accurate diagnosis with subsequent appropriate treatment is crucial for the clinical outcome. The ESSR guidelines are intended to help radiologists in their decision-making and support discussion among clinicians who deal with patients with suspected or proven soft tissue tumors. Potentially malignant lesions recognized by ultrasound should be referred for magnetic resonance imaging (MRI), which also serves as a preoperative local staging modality, with specific technical requirements and mandatory radiological report elements. Radiography may add information about matrix calcification and osseous involvement. Indeterminate lesions, or lesions in which therapy is dependent on histology results, should be biopsied. For biopsy, we strongly recommend referral to a specialist sarcoma center, where an interdisciplinary tumor group, with a specialized pathologist, radiologist, and the surgeon are involved. In sarcoma, a CT scan of the chest is mandatory. Additional staging modalities are entity-specific. There are no evidence-based recommendations for routine follow-up in surgically treated sarcomas. However, we would recommend regular follow-up with intervals dependent on tumor grade, for 10 years after the initial diagnosis. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Entities:
Mesh:
Year: 2015 PMID: 26696086 DOI: 10.1055/s-0035-1569251
Source DB: PubMed Journal: Semin Musculoskelet Radiol ISSN: 1089-7860 Impact factor: 1.777